[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 35 of about 35
1. Park KW, Park JW, Cho SH, Kim YI, Kim SH, Park HS, Lee WJ, Park SJ, Kim DY, Hong EK, Kim CM: [Survival analysis for patients with hepatocellular carcinoma according to stage, liver function and treatment modalities]. Korean J Hepatol; 2006 Mar;12(1):41-54
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Survival analysis for patients with hepatocellular carcinoma according to stage, liver function and treatment modalities].
  • BACKGROUND/AIMS: Hepatocellular carcinoma (HCC) is 3rd leading cause of cancer in Korea and the prognosis for HCC patients is poor.
  • For assessing the present treatment outcome, this study analyzed the three-year survival rate (3-YSR) and the prognostic factors for patients with HCC in Korea.
  • METHODS: Between November 2000 and December 2003, 905 patients with HCC who were diagnosed and treated at the National Cancer Center Korea were enrolled in this study.
  • The overall 3-YSR of the patients with modified UICC stage I, II, III, IVa and IVb were 67.4%, 65.2%, 30.7%, 9.0% and 5.0%, respectively.
  • The modified UICC stage could not differentiate stage I from II, and stage IVa from IVb, on the 3-YSR.
  • The 3-YSR of the Child-Pugh class A patients with modified UICC stage I or II was 85.4% by surgical resection and it was 69.6% by transcatheter chemoembolization (TACE), respectively (P= .461), and those values for patients with stage III were 49.2% and 36.8%, respectively (P=.081).
  • As compared with systemic chemotherapy or conservative therapy, TACE increased the survival rate more for the Child-Pugh class A patients with stage IV.
  • The independent prognostic factors were serum AFP, portal vein thrombosis, the Child-Pugh classification and the stage of HCC.
  • CONCLUSIONS: This follow-up study will be helpful in assessing the results of treatments for HCC and it will provide data for the establishment of a more effective treatment strategy.
  • [MeSH-major] Carcinoma, Hepatocellular / mortality. Liver Neoplasms / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16565605.001).
  • [ISSN] 1738-222X
  • [Journal-full-title] The Korean journal of hepatology
  • [ISO-abbreviation] Korean J Hepatol
  • [Language] kor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


2. Park KW, Park JW, Kim TH, Choi JI, Kim SH, Park HS, Park SJ, Lee WJ, Shin HL, Kim CM: [Five-year survival analysis of a cohort of hepatocellular carcinoma patients who treated at the National Cancer Center, Korea]. Korean J Hepatol; 2007 Dec;13(4):530-42
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Five-year survival analysis of a cohort of hepatocellular carcinoma patients who treated at the National Cancer Center, Korea].
  • BACKGROUND AND AIMS: We investigated the five-year survival outcomes of a large cohort of hepatocellular carcinoma (HCC) patients who were treated at a single institute, and this is a follow-up study of a previous report.
  • METHODS: Nine hundred four HCC patients who were treated at the National Cancer Center Korea were enrolled and they were followed till February 2007.
  • The 5-YSRs of the patients with modified UICC stage I, II and III were 61.2%, 54.4% and 18.4%, respectively, and the median survival time was 4.3 and 3.7 months for the stage IVa and IVb patients, respectively.
  • For the analysis of the treatment modality, surgical resection showed significantly better outcomes for the five-year survival as compared with transcatheter arterial chemoembolization (TACE) for Child-Pugh A patients with modified UICC stage I or II disease (80.1% vs 52.8%, respectively, P<.001), or stage III disease (60.7% vs 17.0%, respectively, P<.001).
  • For patients with advanced stage IVb disease, TACE, systemic chemotherapy and radiotherapy increased the median survival period more than conservative management for the Child-Pugh class A patients.
  • The serum alpha-fetoprotein level, portal vein tumor thrombosis, the Child-Pugh class, the tumor stage, the tumor type and symptoms were related to the prognosis.
  • CONCLUSIONS: This study presented, for the first time, the 5-YSRs of a cohort of HCC patients.
  • [MeSH-major] Carcinoma, Hepatocellular / mortality. Liver Neoplasms / mortality
  • [MeSH-minor] Aged. Chemoembolization, Therapeutic. Cohort Studies. Combined Modality Therapy. Female. Humans. Korea. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Radiotherapy, Conformal. Severity of Illness Index. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18159151.001).
  • [ISSN] 1738-222X
  • [Journal-full-title] The Korean journal of hepatology
  • [ISO-abbreviation] Korean J Hepatol
  • [Language] kor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


3. Hoshino S, Furukawa M, Aragane K, Horimoto M, Suzuki K, Shiono H, Minami M, Okumura M, Kijima T, Kawase I: Successful multimodal treatment in a patient with thymoma accompanied by hepatic metastasis. J Thorac Oncol; 2008 Jan;3(1):98-100
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful multimodal treatment in a patient with thymoma accompanied by hepatic metastasis.
  • Here we report a case of a patient with a Masaoka stage IVb thymoma who was successfully treated using a multimodal strategy including systemic chemotherapy, radiofrequency ablation, and thoracic surgery.
  • Despite complete remission after treatment, the patient developed myasthenia gravis with ptosis and neck drop symptoms.
  • [MeSH-major] Liver Neoplasms. Thymoma / drug therapy. Thymoma / pathology. Thymus Neoplasms / drug therapy. Thymus Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Antineoplastic Agents, Phytogenic / therapeutic use. Biopsy, Needle. Catheter Ablation / methods. Cisplatin / therapeutic use. Combined Modality Therapy. Drug Administration Schedule. Etoposide / therapeutic use. Female. Follow-Up Studies. Humans. Middle Aged. Myasthenia Gravis / drug therapy. Myasthenia Gravis / pathology. Neoplasm Metastasis. Neoplasm Staging. Positron-Emission Tomography. Thymectomy. Time Factors. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18166848.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


Advertisement
4. Miyano M, Kurai O, Hiramatsu S, Yamasaki T, Sasaki E, Adachi K, Oka H: [A case of hepatocellular carcinoma with portal vein thrombus(Vp3)and lung metastases(stage IVB),which responded completely to treatment with Tegafur/Uracil]. Gan To Kagaku Ryoho; 2010 Jun;37(6):1139-43
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of hepatocellular carcinoma with portal vein thrombus(Vp3)and lung metastases(stage IVB),which responded completely to treatment with Tegafur/Uracil].
  • A 65-year-old woman who had diffuse hepatocellular carcinoma(HCC)with tumor thrombus of right portalvein(Vp3) and lung metastases(Stage IVB)was treated by single-agent therapy with tegafur/uracil(UFT).
  • Generally, oral chemotherapy for HCC is not recommended because of the low response rate.
  • We thus conclude that UFT can be an option with low risk of crucial adverse effects in the treatment of selected HCC patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy. Lung Neoplasms / drug therapy. Tegafur / therapeutic use. Thrombosis / etiology. Uracil / therapeutic use
  • [MeSH-minor] Aged. Female. Humans. Neoplasm Staging. Portal Vein / pathology. Remission Induction. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Blood Clots.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20567124.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil
  •  go-up   go-down


5. Eskelin S, Pyrhönen S, Hahka-Kemppinen M, Tuomaala S, Kivelä T: A prognostic model and staging for metastatic uveal melanoma. Cancer; 2003 Jan 15;97(2):465-75
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: To identify factors that independently contribute to overall survival in Stage IVB uveal melanoma and to subcategorize by prognosis.
  • Main covariates were participation in annual review, symptoms, Karnofsky index, metastatic burden, liver function tests, and age.
  • Time on chemotherapy was modeled as a confounder.
  • RESULTS: Of the 91 patients, 85% underwent annual liver imaging and function tests, 63% were asymptomatic, and 73% received chemotherapy.
  • Karnofsky index, largest dimension of the largest metastasis, metastatic burden, serum transaminase, lactate dehydrogenase, and alkaline phosphatase (AP) levels, and time on chemotherapy were strongly (P < 0.001) associated with survival.
  • Karnofsky index (P = 0.013), the largest dimension of the largest metastasis (P = 0.003), and serum AP level (P = 0.042) retained independent significance, adjusting for time on chemotherapy.
  • Observed median survival for Stage IVBa was 14.9 months (95% CI, 11.7-21.3), for Stage IVBb 8.9 months (95% CI, 2.7-13.7), and for Stage IVBc 2.0 months (95% CI, 1.0-3.7).

  • Genetic Alliance. consumer health - Uveal melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 American Cancer Society
  • (PMID = 12518371.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 1.1.1.27 / L-Lactate Dehydrogenase; EC 2.6.1.1 / Aspartate Aminotransferases; EC 2.6.1.2 / Alanine Transaminase; EC 3.1.3.1 / Alkaline Phosphatase
  •  go-up   go-down


6. Ohta H, Shioji K, Maruyama Y, Watanabe K, Aiba T, Baba Y, Seki K, Yanagi M, Iiri T, Ishizuka K, Isokawa O, Nakamura A, Natsui M, Furukawa K, Suzuki Y, Ban-Nai H, Motoyama N, Mori S, Aoyagi Y: [Gemcitabine treatment in patients with stage IV pancreatic cancer and prognostic factors for survival of patients with stage IVb(a retrospective survey at 15 hospitals in Niigata Prefecture)]. Gan To Kagaku Ryoho; 2008 Dec;35(13):2357-61
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gemcitabine treatment in patients with stage IV pancreatic cancer and prognostic factors for survival of patients with stage IVb(a retrospective survey at 15 hospitals in Niigata Prefecture)].
  • We performed a retrospective survey at 15 hospitals in Niigata Prefecture to assess the effectiveness of gemcitabine in patients with stage IV pancreatic cancer and to analyze prognostic factors impacting survival in patients with stage IVb.
  • The subjects were 244 unresectable or metastatic pancreatic cancer patients(IVa 68, IVb 176)who were treated with gemcitabine as first-line therapy.
  • The overall response rate was 6.1% and the median survival time(MST)was 194 days.
  • The MST of stage IVa(312 days)was double that of stage IVb(167 days).
  • Prognostic factors for survival of patients with stage IVb were analyzed(performance status, response rate, liver metastasis, peritonitis carcinomatosa, paraaortic lymph node metastasis)with the Cox proportional hazards model.
  • Performance status, response rate, and liver metastasis were significant factors influencing survival.
  • When we compare an effect of other chemotherapy with GEM, we should treat stage IVa and stage IVb separately, and subdivision is necessary for stage IVb.
  • [MeSH-major] Data Collection / statistics & numerical data. Deoxycytidine / analogs & derivatives. Hospitals / statistics & numerical data. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / pathology

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Health Facilities.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19098402.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


7. Iannitti T, Capone S, Gatti A, Capitani F, Cetta F, Palmieri B: Intracellular heavy metal nanoparticle storage: progressive accumulation within lymph nodes with transformation from chronic inflammation to malignancy. Int J Nanomedicine; 2010;5:955-60
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In 1994, after an emergency hospital admission because of a sport-related thoracic trauma, a right inguinal lymph node biopsy demonstrated Hodgkin's lymphoma Stage IVB (scleronodular mixed cell subtype).
  • Although it was improved by chemotherapy, the disease suddenly relapsed, and a further lymph node biopsy was performed in 1998 confirming the same diagnosis.
  • Despite further treatment, the patient died of septic shock in 2004, at the age of 38 years.
  • Retrospective analysis of the various specimens showed intracellular heavy metal nanoparticles within lymph node, bone marrow, and liver samples by field emission gun environmental scanning electron microscopy and energy dispersive spectroscopy.
  • Heavy metals from environmental pollution may accumulate in sites far from the entry route and, in genetically conditioned individuals with tissue specificity, may act as cofactors for chronic inflammation or even malignant transformation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Toxicol Appl Pharmacol. 2009 Apr 15;236(2):154-65 [19371627.001]
  • [Cites] Annu Rev Pathol. 2009;4:151-74 [19400691.001]
  • [Cites] Environ Health Perspect. 2009 May;117(5):A190 [19478977.001]
  • [Cites] Environ Health Perspect. 2009 Aug;117(8):A340; author reply A340-1 [19672380.001]
  • [Cites] Dtsch Med Wochenschr. 2009 Sep;134(39):1944-8 [19760557.001]
  • [Cites] Inhal Toxicol. 2009 Nov;21(13):1099-107 [19814607.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2009;:491-6 [20008234.001]
  • [Cites] Environ Mol Mutagen. 2010 Mar;51(2):89-111 [19708067.001]
  • [Cites] Proc Natl Acad Sci U S A. 2010 Apr 6;107(14):6400-5 [20308568.001]
  • [Cites] Environ Health Perspect. 2010 Jun;118(6):A240 [20515720.001]
  • [Cites] Chem Biol Interact. 2010 Nov 5;188(2):276-88 [20430016.001]
  • [Cites] Eur Spine J. 2007 Jul;16(7):1055-61 [17256156.001]
  • [Cites] J Biol Chem. 1999 Dec 17;274(51):36207-12 [10593907.001]
  • [Cites] Biol Trace Elem Res. 2001 Nov;83(2):133-8 [11762530.001]
  • [Cites] Oncol Rep. 2002 Jan-Feb;9(1):61-4 [11748456.001]
  • [Cites] J Bone Joint Surg Br. 2003 Aug;85(6):913-7 [12931818.001]
  • [Cites] Mutat Res. 2003 Dec 10;533(1-2):3-36 [14643411.001]
  • [Cites] Toxicology. 2004 Oct 1;202(3):249-69 [15337587.001]
  • [Cites] Sci Total Environ. 1985 Apr;42(3):237-43 [4001919.001]
  • [Cites] Int J Hematol. 1996 Oct;64(3-4):257-62 [8923788.001]
  • [Cites] Postepy Hig Med Dosw. 1996;50(4):383-94 [9019747.001]
  • [Cites] J Bone Joint Surg Am. 1998 Feb;80(2):268-82 [9486734.001]
  • [Cites] J Bone Joint Surg Am. 1998 Oct;80(10):1447-58 [9801213.001]
  • [Cites] Recent Results Cancer Res. 1998;154:3-21 [10026990.001]
  • [Cites] Med Pr. 2005;56(3):249-55 [16218139.001]
  • [Cites] Environ Mol Mutagen. 2007 Jan;48(1):30-7 [17163505.001]
  • [Cites] Can Nurse. 2007 Jan;103(1):22-6 [17269580.001]
  • [Cites] Environ Health Perspect. 2007 Sep;115(9):1264-70 [17805414.001]
  • [Cites] Mutat Res. 2008 Jun 30;654(1):45-51 [18541454.001]
  • [Cites] Arch Toxicol. 2008 Aug;82(8):493-512 [18496671.001]
  • [Cites] Crit Rev Toxicol. 2008;38(8):645-74 [18720105.001]
  • [ErratumIn] Int J Nanomedicine. 2011;6:239. Capitani, Frederico [corrected to Capitani, Federico]
  • (PMID = 21187947.001).
  • [ISSN] 1178-2013
  • [Journal-full-title] International journal of nanomedicine
  • [ISO-abbreviation] Int J Nanomedicine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Metals, Heavy
  • [Other-IDs] NLM/ PMC3010157
  • [Keywords] NOTNLM ; Hodgkin’s lymphoma / environmental exposure / heavy metals / host–particle interactions / nanoparticles / nanotoxicity
  •  go-up   go-down


8. Mizuiri H, Hihara J, Okada M: [CDDP+CPT-11 therapy is useful for stage IVb esophageal small cell carcinoma]. Gan To Kagaku Ryoho; 2009 May;36(5):831-4
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [CDDP+CPT-11 therapy is useful for stage IVb esophageal small cell carcinoma].
  • An esophageal small cell carcinoma was pointed out at another clinic by gastrointestinal fiberscopy.
  • He was diagnosed as esophageal small cell carcinoma with mediastinum lymph node, pancreas and multiple liver metastasis by CT scan.
  • Then he was administered CDDP+CPT-11 therapy.
  • At one cycle after the first infusion therapy, primary tumor, pancreas and liver metastasis were markedly reduced.
  • Five cycles after the first infusion therapy, he was diagnosed with a lymph node recurrence around the pancreas on January 19, 2004.
  • Then we started CBDCA and VP-16 combination therapy as second-line chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / analogs & derivatives. Carcinoma, Small Cell / drug therapy. Carcinoma, Small Cell / pathology. Cisplatin / therapeutic use. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / pathology
  • [MeSH-minor] Esophagoscopy. Fatal Outcome. Humans. Male. Middle Aged. Neoplasm Staging. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19461188.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


9. Tanaka T, Fujita H, Matono S, Nagano T, Nishimura K, Murata K, Shirouzu K, Suzuki G, Hayabuchi N, Yamana H: Outcomes of multimodality therapy for stage IVB esophageal cancer with distant organ metastasis (M1-Org). Dis Esophagus; 2010 Nov;23(8):646-51
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of multimodality therapy for stage IVB esophageal cancer with distant organ metastasis (M1-Org).
  • Esophageal cancer patients with distant organ metastasis have usually been treated only to palliate symptoms without multimodality therapy.
  • The current study evaluates the role of multimodality therapy in esophageal squamous cell cancer patients with distant organ metastasis.
  • Between February 1988 and January 2007, 80 esophageal squamous cell cancer patients with distant organ metastases were treated at our institution.
  • Multimodality therapy was performed in 58 patients: 43 patients received chemoradiotherapy, 13 underwent surgery followed by chemotherapy and/or radiation therapy, and two received chemotherapy or chemoradiotherapy followed by surgery.
  • Thirteen patients received single-modality therapy; chemotherapy, radiotherapy, or surgery alone.
  • The metastatic organ was the liver (n= 40), the lungs (n= 33), bone (n= 10), and other (n= 6).
  • There was no difference in the median survival among the sites of organ metastasis, lung, liver, or bone (P= 0.8786).
  • The survival of patients treated with multimodality therapy was significantly better than that of the patients who received single-modality therapy or best supportive care alone (P < 0.0001).
  • In patients treated with multimodallity therapy, there was no difference in survival for patients treated with surgery compared with patients treated without surgery (P= 0.1291).
  • However, these results suggested that multimodality therapy could improve survival of the esophageal squamous cell cancer patients with distant organ metastasis.

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Copyright the Authors. Journal compilation © 2010, Wiley Periodicals, Inc. and the International Society for Diseases of the Esophagus.
  • (PMID = 20545979.001).
  • [ISSN] 1442-2050
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Tsujie M, Shibata N, Nomura T, Tanaka T, Morimoto T, Fujita S, Kitani K, Nakahira S, Okuda H, Takeda M: [A patient with stage IVb small cell carcinoma of the esophagus who survived 23 months after systemic cancer chemotherapy]. Gan To Kagaku Ryoho; 2003 Feb;30(2):271-5
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A patient with stage IVb small cell carcinoma of the esophagus who survived 23 months after systemic cancer chemotherapy].
  • X-ray barium studies and upper gastrointestinal endoscopic examination revealed an irregular ulcerated lesion in the lower portion of the esophagus, which was diagnosed based on pathology tests as small cell carcinoma.
  • A computed tomography scan showed para-aortic lymph node swelling and multiple liver metastases.
  • Treatment with chemotherapy of CDDP and 5-FU showed clinical complete remission.
  • However, the patient died of paraaortic lymph node metastasis, recurrence of the original lesion, multiple liver metastasis and brain metastasis 23 months after diagnosis.
  • The prognosis of small cell carcinoma of the esophagus is quite unfavorable because of the highly aggressive biological behavior.
  • However, if remission is achieved by chemotherapy as in this case, a better prognosis is possible.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Small Cell / drug therapy. Esophageal Neoplasms / drug therapy
  • [MeSH-minor] Cisplatin / administration & dosage. Combined Modality Therapy. Drug Administration Schedule. Etoposide / administration & dosage. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Neoplasm Staging. Survivors

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12610878.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; CF regimen; VP-P protocol
  • [Number-of-references] 14
  •  go-up   go-down


11. Fukuda Y, Fujio N, Takatori H, Tsukazaki T, Terakura M, Mayumi K, Koyama I, Tsukazaki Y, Osugi H: [Complete response to treatment with low-dose FP therapy in a patient with stage IVB primary hepatocellular carcinoma with multiple lung and bone metastases]. Gan To Kagaku Ryoho; 2004 Jan;31(1):107-11
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Complete response to treatment with low-dose FP therapy in a patient with stage IVB primary hepatocellular carcinoma with multiple lung and bone metastases].
  • We report a case in which low-dose FP (5-fluorouracil/cisplatin, 5-FU/CDDP) therapy was remarkably effective for stage IVB advanced hepatocellular carcinoma (HCC) with lung and bone metastases.
  • Chest computed tomography (CT) showed multiple bilateral lung metastases and abdominal CT showed a tumor 12 x 11 x 10 cm in diameter in the right, iliac bone.
  • No recurrent sign was found in the liver except for the accumulation of Lipiodol.
  • Low-dose FP therapy of 2 cycles was performed.
  • The levels of serum AFP and PIVKA-II decreased to 374 ng/ml from 59,300 and to 35 AU/ml from 25,700, respectively, after this therapy.
  • No sign of recurrence was seen during the 13 months of follow-up after low-dose FP therapy.
  • Her quality of life (QOL) was fair during this therapy.
  • Low-dose FP therapy is possibly useful for patients with stage IVB advanced HCC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / secondary. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy. Lung Neoplasms / secondary
  • [MeSH-minor] Aged. Aged, 80 and over. Cisplatin / administration & dosage. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Humans. Neoplasm Staging. Quality of Life. Remission Induction

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14750333.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; CF regimen
  •  go-up   go-down


12. Mizuuchi Y, Anbe K, Yamagata N, Ohji Y, Kanamoto K, Yao T: [A case of stage IVb small cell carcinoma of the esophagus obtained prolonged survival after combined modality therapy]. Gan To Kagaku Ryoho; 2010 Apr;37(4):715-8
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of stage IVb small cell carcinoma of the esophagus obtained prolonged survival after combined modality therapy].
  • Small cell carcinoma of the esophagus is a relatively rare disease, and its prognosis is quite poor, because of its rapid progression.
  • Upper gastrointestinal endoscopic examination(GIS)revealed an ulcerated lesion in the lower portion of the thoracic esophagus, and we diagnosed small cell carcinoma by a biopsy specimen.
  • A computer tomography scan revealed solitary liver metastasis, and lymph node swelling on the left side of the superior mesenteric artery.
  • So, we started chemotherapy with VP-16 and CDDP, according to a regimen for small cell carcinoma of the lung.
  • After 4 courses of chemotherapy, the primary lesion, liver metastasis, and lymph node swelling had disappeared, so we decided it was a complete response.
  • 20 months later, follow-up GIS revealed low elevated lesion at the margins of an ulcerated scar, and diagnosed squamous cell carcinoma by the biopsy specimen.
  • The patient received 60 Gy radiotherapy in total, and is still alive 6 years after diagnosis without any evidence of recurrence.
  • [MeSH-major] Carcinoma, Small Cell / drug therapy. Carcinoma, Small Cell / radiotherapy. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Biopsy. Combined Modality Therapy. Esophagoscopy. Female. Humans. Neoplasm Staging. Remission Induction. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20414033.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


13. Ohbu M, Maruyama M, Kato K, Koide A, Hasegawa K, Maruyama S, Takashima I, Ebuchi M: [A case of gastric cancer with extraordinary liver metastasis effectively treated by adjuvant chemotherapy]. Gan To Kagaku Ryoho; 2004 Oct;31(11):1682-4
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of gastric cancer with extraordinary liver metastasis effectively treated by adjuvant chemotherapy].
  • This was an extraordinary liver metastasis case with complication when the patient, a 70-year-old male, was diagnosed with stomach cancer for the first time.
  • However, the patient has been in remission and is a long-term survivor due to an active chemotherapy after the operation.
  • He was diagnosed with stomach cancer by endoscopy.
  • The liver dysfunction was revealed in the blood biochemistry inspection.
  • The abdominal CT revealed that the stomach cancer had spread to the whole liver.
  • Distal gastrectomy was performed on May 22, 1997.
  • Final findings: M, type3, T3 (SE), N2, H3, P0, CY0, and Stage IVb.
  • The 5-FU based chemotherapy was performed and a complete response was temporarily obtained.
  • However, it has recurred one year later and two or more kinds of chemotherapy have continued.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Stomach Neoplasms / pathology
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Chemotherapy, Adjuvant. Humans. Male

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15553682.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


14. Matsuda T, Shikata S, Minato H, Aikawa I: [Two cases of advanced biliary tract cancer successfully treated with gemcitabine combination chemotherapy]. Gan To Kagaku Ryoho; 2008 Oct;35(10):1779-82
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of advanced biliary tract cancer successfully treated with gemcitabine combination chemotherapy].
  • Case 1: A man in his sixties underwent extended right lobectomy of the liver for hepatic hilar cholangiocarcinoma (stage III, fCur B)in July2002.
  • CT scans revealed cancerous pleuritis in March 2005, and he was treated with the chemotherapy of GEM alone as first-line, combined chemotherapy of S-1 and GEM as second-line, and CDDP and GEM as third-line treatment.
  • These therapies have been effective for about 20 months.
  • Case 2: A woman in her sixties was diagnosed with advanced gallbladder cancer(stage IVb)in September 2005.
  • She was given combined chemotherapy of S-1+GEM as first-line, and CDDP+GEM as second-line treatment.
  • Histopathologic examinations of the resected specimen of the liver involved by the tumor showed the increased infiltration of inflammatorycells and fibrosis.
  • These patients have been managed on an outpatient basis with good QOL and cancer controlled.
  • Although there has been no established standard regimen, the combined chemotherapy based on GEM will be a provisional standard regimen for patients with advanced biliarytract cancers.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biliary Tract Neoplasms / drug therapy. Biliary Tract Neoplasms / pathology. Deoxycytidine / analogs & derivatives
  • [MeSH-minor] Biomarkers, Tumor / blood. Female. Humans. Male. Neoplasm Staging. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Biliary Tract Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18931588.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


15. Shibata S, Paz B, Ellenhorn J, Vora N, Somlo G, Koczywas M, Lim D, Frankel P, Wagman L, Doroshow J: A phase II trial of neoadjuvant chemotherapy (NCT), organ-sparing surgery, and radiation in squamous cell head and neck cancer (SCHNC): Results of neoadjuvant chemotherapy. J Clin Oncol; 2004 Jul 15;22(14_suppl):5617

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of neoadjuvant chemotherapy (NCT), organ-sparing surgery, and radiation in squamous cell head and neck cancer (SCHNC): Results of neoadjuvant chemotherapy.
  • : 5617 Background: NCT with radiation has facilitated organ-sparing treatment in locally advanced SCHNC.
  • METHODS: Pts had resectable untreated stage III, IV SCHNC of the oral cavity, oropharynx, hyopharynx, or larynryx, and stage II cancer of the base of tongue, hypopharynx, and larynx.
  • An ANC ≥ 1500/μl, platelet ≥ 100K/μl, serum creatinine ≤ 1.5mg/dl, bilirubin ≤ 1.5 mg/dl, liver function tests < 2.5 ULN, Karnofsky Performance Status (KPS) ≥ 60%, and signed informed consent were required.
  • Pts had stage III (9), IVa (13), IVb (2), and stage II (1) disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015276.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Nagao S, Fujiwara K, Oda T, Ishikawa H, Koike H, Tanaka H, Kohno I: Docetaxel and carboplatin combination chemotherapy in advanced or recurrent cervix cancer of the uterus. A pilot study. J Clin Oncol; 2004 Jul 15;22(14_suppl):5099

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Docetaxel and carboplatin combination chemotherapy in advanced or recurrent cervix cancer of the uterus. A pilot study.
  • : 5099 Background: This is a pilot study to assess an efficacy and safety of combination chemotherapy of docetaxel and carboplatin in advanced or recurrent uterine cervix cancer for the future trial.
  • METHODS: The patients eligible for this study were those who were histologically confirmed (squamous cell carcinoma, adenocarcinoma, or adenosquamous cell carcinoma), advanced (stage IB2-IV) or recurrent uterine cervix cancer.The patient must have measurable lesion and must have sufficient bone marrow, renal, and liver function.
  • Chemotherapy was repeated 1-6 courses depending on the purpose of the therapy.
  • However, confirmation of the objective response no less than 4 weeks after criteria for response are first met was not required in patients who underwent chemotherapy as a neoadjuvant setting.
  • Distribution of stage was IB2; 1, IIB; 6, IIIB; 2, IVB; 2, Recurrent; 2.
  • There were 6 squamous cell carcinomas, 5 adenocarcinomas and 1 adenosquamous cell carcinoma.
  • All 5 adenocarcinoma patients under neoadjuvant chemotherapy setting responded including 1 pathological CR.
  • CONCLUSIONS: Combination of docetaxel and carboplatin is effective and safe treatment for uterine cervix cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015322.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Sasada T, Denno R, Tanaka T, Kanai M, Mizukami Y, Kohno S, Takabayashi A: Intra-arterial infusion chemotherapy with 5-fluorouracil and cisplatin in advanced pancreatic cancer: a feasibility study. Am J Clin Oncol; 2008 Feb;31(1):71-8
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intra-arterial infusion chemotherapy with 5-fluorouracil and cisplatin in advanced pancreatic cancer: a feasibility study.
  • OBJECTIVE: Our aim was to examine the efficacy and tolerability of intra-arterial infusion chemotherapy with 5-fluorouracil (5-FU) and cisplatin in advanced pancreatic cancer.
  • METHODS: Sixteen patients with unresectable locally advanced or metastatic pancreatic cancer (12 Stage IVa and 4 Stage IVb with liver metastasis) were enrolled.
  • The catheter for intra-arterial infusion was placed at the position to distribute chemotherapeutic drugs to both the pancreatic tumor and the liver.
  • RESULTS: In 12 Stage IVa locally advanced patients, the response rate was 58.3% (7 partial response).
  • The median survival time was 22.0 months, and the 1-, 2-, and 3-year survival rates were 83.3%, 41.7%, and 16.7%, respectively.
  • The locally advanced patients treated with intra-arterial infusion chemotherapy showed significantly better survival than the control patients.
  • In contrast, Stage IVb patients with liver metastasis showed no response to the treatment (response rate, 0%).
  • Treatment was discontinued in 2 patients until recovery from hematologic or hepatic toxicity, but fatal adverse events were not observed.
  • CONCLUSION: These results suggest that intra-arterial infusion chemotherapy with 5-FU and cisplatin is tolerable and feasible treatment to improve the prognosis in locally advanced pancreatic cancer patients without distant metastasis.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Liver Neoplasms / drug therapy. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Feasibility Studies. Female. Fluorouracil / administration & dosage. Humans. Infusions, Intra-Arterial. Male. Maximum Tolerated Dose. Middle Aged. Pancreaticoduodenectomy. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18376231.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


18. Nakada T, Nagayama K, Hiramoto J, Tsuruta Y, Murakami S, Sakabe S: Complete regression of esophageal cancer with concomitant liver metastasis achieved by concurrent chemoradiation therapy. Int J Clin Oncol; 2002 Jun;7(3):192-6
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete regression of esophageal cancer with concomitant liver metastasis achieved by concurrent chemoradiation therapy.
  • We report a patient with esophageal cancer with concomitant liver metastasis in whom complete response was achieved by chemoradiation therapy.
  • A 66-year-old man was diagnosed as having stage IVB esophageal cancer with synchronous metastasis in the liver and cardiac lymph node, and concurrent chemoradiation therapy was started.
  • The chemotherapy, consisting of 5-fluorouracil (300 mg/body per day, continuous infusion) and low-dose cisplatin (5 mg/body per day on 1-5 days every week), was performed for 7 weeks.
  • In addition, radiation therapy (2 Gy/day on 1-5 days every week) was employed for both the local and the metastatic lesions, along with the chemotherapy.
  • Throughout the course of this therapy, the patient did not experience severe toxicity, and this chemoradiation therapy resulted in complete regression of both the local and the metastatic diseases.
  • Subsequently, he was followed-up as an outpatient without any maintenance therapy, and he has been free of disease for 38 months after completion of the therapy.
  • This concurrent chemoradiation therapy may be effective for esophageal cancer even with visceral metastasis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / therapy. Esophageal Neoplasms / therapy. Liver Neoplasms / therapy. Radiotherapy
  • [MeSH-minor] Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Disease-Free Survival. Fluorouracil / administration & dosage. Humans. Lymphatic Metastasis. Male. Remission Induction. Tomography, X-Ray Computed


19. Honda M, Izumi Y, Miura A, Kato T, Monma K, Funada N: [A case of advanced esophageal cancer with large liver metastasis successfully treated with FAP therapy]. Gan To Kagaku Ryoho; 2008 Apr;35(4):629-31
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced esophageal cancer with large liver metastasis successfully treated with FAP therapy].
  • A 70-year-old man with dysphagia was diagnosed as advanced esophageal cancer by a primary doctor, and he was admitted to our hospital for treatment in February, 2004.
  • The pretreatment diagnosis was basaloid squamous carcinoma, Mt area, T4 (aorta) , N2 (No. 107) , M1 (liver), Stage IVb performed systemic chemotherapy by FAP (5-fluorouracil ( 5-FU)+doxorubicin (DXR)+cisplatin (CDDP) ) from March, 2004.
  • After 4 courses, the local tumor almost entirely disappeared, and the liver metastasis was obviously reduced.
  • We continued chemotherapy afterwards.
  • It is very important to perform FAP repeatedly, for local and metastatic lesion of esophageal cancer while maintaining the patient's general condition and avoiding adverse events.
  • [MeSH-major] Cisplatin / therapeutic use. Doxorubicin / therapeutic use. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / pathology. Fluorouracil / therapeutic use. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Humans. Male. Neoplasm Staging


20. Nagao S, Fujiwara K, Oda T, Ishikawa H, Koike H, Tanaka H, Kohno I: Combination chemotherapy of docetaxel and carboplatin in advanced or recurrent cervix cancer. A pilot study. Gynecol Oncol; 2005 Mar;96(3):805-9
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination chemotherapy of docetaxel and carboplatin in advanced or recurrent cervix cancer. A pilot study.
  • OBJECTIVES: This is a pilot study for a future trial to assess the efficacy and safety of combination chemotherapy with docetaxel and carboplatin in advanced or recurrent uterine cervix cancer.
  • METHODS: The patients eligible for this study had histologically confirmed, advanced (stage IB2-IV) or recurrent uterine cervix cancer.
  • Eligible patients had measurable lesions and must have sufficient bone marrow, renal, and liver functions.
  • Chemotherapy was repeated in 1-6 courses depending on the purpose of the therapy.
  • The distribution of stage was IB2, 3; IIB, 8; IIIB, 3; IVB, 1; recurrent, 2.
  • There were 9 squamous cell carcinomas, 6 adenocarcinomas, 1 adenosquamous cell carcinoma, and 1 small cell carcinoma.
  • All 5 adenocarcinoma patients in the neoadjuvant chemotherapy group responded including 1 pathological CR.
  • CONCLUSIONS: The combination of docetaxel and carboplatin is an effective and safe treatment for uterine cervix cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Carboplatin / administration & dosage. Carboplatin / adverse effects. Female. Humans. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Pilot Projects. Taxoids / administration & dosage. Taxoids / adverse effects

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15721429.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; BG3F62OND5 / Carboplatin
  •  go-up   go-down


21. Shim JH, Park JW, Nam BH, Lee WJ, Kim CM: Efficacy of combination chemotherapy with capecitabine plus cisplatin in patients with unresectable hepatocellular carcinoma. Cancer Chemother Pharmacol; 2009 Feb;63(3):459-67
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of combination chemotherapy with capecitabine plus cisplatin in patients with unresectable hepatocellular carcinoma.
  • PURPOSE: The aim was to assess the efficacy and safety of capecitabine (X) plus cisplatin (P) in patients with hepatocellular carcinoma (HCC).
  • METHODS: We retrospectively analyzed the data of 178 assessable among 195 consecutive HCC patients ineligible for curative therapy who were treated with XP at the National Cancer Center Korea between January 2002 and July 2007.
  • RESULTS: One patient (0.5%) had modified UICC stage II tumors, 12 (6.7%) had stage III, 51 (28.7%) had stage IVa, and 114 (64.1%) had stage IVb.
  • The median time to progression (TTP) and median overall survival were 2.8 months (95% CI 2.5-3.1 months) and 10.5 months (95% CI 7.9-13.1 months), respectively.
  • CONCLUSIONS: Although XP chemotherapy produced moderate survival outcomes in advanced HCC patients, it was efficacious in the treatment of HCC patients with a uninodular or no residual intrahepatic tumor, especially women, regardless of extrahepatic tumor status.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18437384.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


22. Yamashita S, Sakon M, Hiura Y, Nakano K, Higaki N, Murakami M, Hayashida H, Kan K, Ichihara T: [A case of gemcitabine-based chemo-radiation therapy for unresectable pancreatic cancer with liver metastases]. Gan To Kagaku Ryoho; 2007 Nov;34(12):2010-2
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of gemcitabine-based chemo-radiation therapy for unresectable pancreatic cancer with liver metastases].
  • We report a case of advanced unresectable pancreatic cancer with multiple liver metastases (cT4N x M1, stage IVb).
  • Abdominal CT scan revealed the body and tail of pancreatic cancer and multiple liver metastases.
  • Chemo-radiation therapy (CRT) with GEM 1000 mg/body was given once a week on days 1, 8 and 15 for 3 weeks.
  • The radiotherapy dose was 45 Gy (1.5 Gy x 2/day, 15 days).
  • After CRT, the patient was treated thereafter by the combination chemotherapy with GEM and S-1.
  • [MeSH-major] Deoxycytidine / analogs & derivatives. Liver Neoplasms / drug therapy. Liver Neoplasms / radiotherapy. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Antigens, Neoplasm / blood. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / blood. Combined Modality Therapy. Humans. Male. Time Factors. Tomography, X-Ray Computed


23. Ehara K, Tsutsumi K, Kinoshita Y, Ueno M, Mine S, Udagawa H: [A case of advanced esophageal cancer with liver metastases: efficacy of combination therapy of docetaxel/cisplatin/5-FU]. Gan To Kagaku Ryoho; 2008 Aug;35(8):1375-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced esophageal cancer with liver metastases: efficacy of combination therapy of docetaxel/cisplatin/5-FU].
  • The combination chemotherapy with docetaxel/CDDP/5-FU(DCF)for head and neck squamous carcinoma(SCC) has been widely accepted.
  • It seems quite natural that DCF therapy is expected to be equally effective against esophageal SCC because of their histological similarity.
  • In this report, we present a case of unresectable advanced esophageal SCC with multiple liver metastases which showed remarkable regression by DCF therapy, with relatively slight adverse effects.
  • Abdominal CT scan showed multiple liver metastases with para-aortic lymph node involvement.
  • The clinical stage diagnosis was T3N4M1, Stage IVB, obviously non-resectable far-advanced esophageal SCC.
  • Systemic chemotherapy with DCF was started as the initial treatment.
  • The chemotherapy regimen was as follows.
  • Each course was followed by a 23-day drug-free period, and the entire course was repeated every 28 days.
  • Ten cycles of this DCF chemotherapy were carried out.
  • After 8 cycles, the liver metastases were judged as CR and para-aortic lymph nodes showed a partial response(PR)by CT scan.
  • Until this writing, we added 2 more cycles of DCF therapy for the recurrent para-aortic and inguinal lymph node metastasis.
  • We conclude that DCF therapy is potentially very effective for advanced esophageal SCC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / therapeutic use. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / pathology. Fluorouracil / therapeutic use. Liver Neoplasms / drug therapy. Taxoids / therapeutic use
  • [MeSH-minor] Biomarkers, Tumor / blood. Esophagoscopes. Female. Humans. Middle Aged. Neoplasm Staging. Tomography, X-Ray Computed


24. Loizzi V, Rossi C, Cormio G, Cazzolla A, Altomare D, Selvaggi L: Clinical features of hepatic metastasis in patients with ovarian cancer. Int J Gynecol Cancer; 2005 Jan-Feb;15(1):26-31
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical features of hepatic metastasis in patients with ovarian cancer.
  • The purpose of this study was to investigate the clinical features of hepatic metastasis in patients with epithelial ovarian cancer.
  • From 1998 to 2002, all women with hepatic metastasis from ovarian cancer were identified at the University of Bari.
  • Twenty-nine patients identified included one having stage IIC, one stage IIIA, two stage IIIB, 17 stage IIIC, and eight stage IVB.
  • Eight women had hepatic metastasis at the time of the diagnosis of ovarian cancer (group I), 10 patients had hepatic metastasis as first recurrence (group II), and 11 (group III) as a second relapse.
  • The median survival from the time of liver metastasis diagnosis was 19 months in group I patients, 24 months in group II patients, and 10 months in group III patients.
  • Cell type, performance status at the time of the primary tumor diagnosis, number of hepatic lesions, the presence of other sites of disease at the time of hepatic metastasis, and platinum-based chemotherapy were significantly related to survival.
  • Better performance status, serous cell-type tumor, single hepatic lesion, the absence of other sites of disease, and platinum-based chemotherapy are good prognostic factors.
  • [MeSH-major] Adenocarcinoma / diagnosis. Liver Neoplasms / diagnosis. Neoplasm Recurrence, Local. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Female. Humans. Middle Aged. Neoplasm Staging. Risk Factors. Survival Analysis

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15670293.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


25. Lorvidhaya V, Kamnerdsupaphon P, Chitapanarux I, Sukthomya V, Tonusin A: Cisplatin and gemcitabine in patients with metastatic cervical cancer. Gan To Kagaku Ryoho; 2004 Jul;31(7):1057-62
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cisplatin and gemcitabine in patients with metastatic cervical cancer.
  • PURPOSE: To determine the therapeutic efficacy of cisplatin plus gemcitabine in the treatment of patients with metastatic cervical cancer.
  • There were 14 patients with stage IVB cervical cancer who were previously untreated.
  • The sites of metastases were 10 in the lungs, 5 in the supraclavicular nodes, 9 in the paraaortic nodes, 4 in the liver, 3 in the inguinal nodes, 5 in both supraclavicular nodes and lungs, 9 in both supraclavicular and paraaortic nodes, 1 in both supraclavicular and inguinal nodes, 1 in both lung and inguinal nodes, 2 in both lung and paraaortic nodes and 2 in both liver and lungs.
  • Fine needle biopsies were done in all metastatic sites except for multiple lung and multiple liver metastases.
  • Eleven patients were not assessable because of patient refusal for further treatment and loss of follow up.
  • There were 3 (5.8%) patients who developed grade 4 neutropenia and fever.
  • There were no treatment related deaths.
  • The median time to progression was 8.3 months and the median survival was 9.6 months.
  • CONCLUSION: In this study of patients with metastatic cervical cancer, the combination of cisplatin and gemcitabine treatment induced a high response rate.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Deoxycytidine / analogs & derivatives. Lymph Nodes / pathology. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Agranulocytosis / chemically induced. Anemia / chemically induced. Cisplatin / administration & dosage. Female. Humans. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Lymphatic Metastasis. Middle Aged. Survival Rate. Thrombocytopenia / chemically induced


26. Sunamura M, Kobari M, Shibuya K, Takeda K, Matsuno S: [The role of preoperative staging for pancreatic cancer]. Nihon Geka Gakkai Zasshi; 2000 Feb;101(2):212-6
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The role of preoperative staging for pancreatic cancer].
  • Despite the poor prognosis of pancreatic carcinoma patients, surgical resection remains the only potentially curative treatment.
  • According to the report of a national survey of pancreatic cancer in 1997, patients with S0 or S1, RP0 or RP1, and N0 or N1 disease have longer survival periods compared with patients with S2, RP2, and N2 disease.
  • Therefore patients classified as Stage I, Stage II, or Stage III are recognized as candidates for surgical resection.
  • Patients classified as Stage IVb because of positive P factor or positive H factor are selected for conservative treatment such as chemotherapy and irradiation.
  • It remains to be clarified whether patients classified as Stage IVa should undergo surgical resection or not.
  • Future prospective randomized studies of patients with Stage IVa disease will reveal whether surgical resection or chemoradiation is effective.
  • Helical CT is useful to evaluate S and RP factors for definitive preoperative staging.
  • CT-AP can reveal occult metastases to the liver.

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10734639.001).
  • [ISSN] 0301-4894
  • [Journal-full-title] Nihon Geka Gakkai zasshi
  • [ISO-abbreviation] Nihon Geka Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] JAPAN
  •  go-up   go-down


27. Kishiwada M, Kawarada Y, Taoka H, Isaji S: Management of advanced pancreatic cancer: staging laparoscopy and immunochemotherapy--a new treatment strategy. Hepatogastroenterology; 2002 Nov-Dec;49(48):1704-6
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of advanced pancreatic cancer: staging laparoscopy and immunochemotherapy--a new treatment strategy.
  • BACKGROUND/AIMS: Pancreatic cancer remains a challenging disease with a dismal prognosis.
  • METHODOLOGY: Fifty-five patients admitted to our Department between April 1993 and April 2000 for resection of pancreatic cancer were the subjects of this study.
  • Staging laparoscopy was performed in 16 of the patients, and 2-ICA was used to treat three of 16 because they were found to have small liver metastases during staging laparoscopy.
  • RESULTS: According to the TNM staging system (UICC), 9 (56%) in the 16 patients who underwent staging laparoscopy were found to have Stage IVb disease, 4 (25%) to have Stage IVa disease and only 3 (19%) to have Stage III disease.
  • The three patients with small liver metastases received 2-ICA therapy.
  • The metastatic lesions in the liver had completely disappeared in one patient, and decreased to about half the size in the other two cases.
  • CONCLUSIONS: Staging laparoscopy is useful for correctly diagnosing tumor stage in pancreatic cancer patients and selecting appropriate treatment.
  • The 2-ICA therapy is a new and effective method of treatment for advanced cases.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Fluorouracil / therapeutic use. Immunotherapy. Interleukin-2 / therapeutic use. Laparoscopy. Leucovorin / therapeutic use. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Neoplasm Staging. Treatment Outcome

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12397771.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interleukin-2; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


28. Kaman L, Behera A, Singh G, Nedounsejiane M: Radical surgery for incidental cancer gallbladder after laparoscopic cholecystectomy. Trop Gastroenterol; 2009 Oct-Dec;30(4):233-6
MedlinePlus Health Information. consumer health - Gallbladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radical surgery for incidental cancer gallbladder after laparoscopic cholecystectomy.
  • OBJECTIVE: To report our experience in the management of incidentally detected carcinoma gall bladder and establishment of a treatment protocol.
  • METHOD: Retrospective review of 7 patients with incidentally detected carcinoma gall bladder during and after laparoscopic cholecystectomy for presumed benign disease.
  • Clinical and histopathological data, treatment and long term outcome of all seven patients were reviewed.
  • Exploratory laparotomy and radical surgery with curative intent consisting of liver resection, lymphadenectomy of the pedicle and excision of the port site were performed in all patients.
  • RESULTS: Liver resection including the segments IVB and V was done in 5 patients and in 2 patients resection of a wedge of hepatic parenchyma of more than 2 cm thickness including the gall bladder bed was carried out.
  • Postoperatively, 2 patients developed fever and 1 patient had minimal altered blood in the nasogastric tube aspirate.
  • All 7 patients had disease of pathological stage II and beyond.
  • All patients received adjuvant chemotherapy.
  • CONCLUSION: Re-exploration and aggressive resection with adjuvant chemotherapy for incidental carcinoma of the gallbladder is safe and offers hope for long term survival.
  • [MeSH-minor] Female. Humans. Incidental Findings. Lymph Node Excision. Male. Middle Aged. Postoperative Complications. Reoperation. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20426289.001).
  • [ISSN] 0250-636X
  • [Journal-full-title] Tropical gastroenterology : official journal of the Digestive Diseases Foundation
  • [ISO-abbreviation] Trop Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


29. Yamaguchi T, Takahashi H, Kagawa R, Takeda R, Sakata S, Yamamoto M, Nishizaki D, Takamatsu T, Iwasa Y: Successfully-treated mesenteric non-Hodgkin's lymphoma involving hepatic mass--a case report. Gan To Kagaku Ryoho; 2007 May;34(5):783-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A mesenteric diffuse large B-cell lymphoma which also involves the liver is very rare.
  • We describe herein a mesenteric diffuse large B-cell lymphoma with hepatic involvement successfully treated by the combination of surgical resection and multiagent chemotherapy.
  • Abdominal computed tomography showed a mass in the mesenterium at the ileocoecal region and multiple mass in the liver.
  • Gallium scintigram showed focal hot uptake at the ileocoecal region and multiple areas of increased Gallium uptake in the liver.
  • With the diagnosis of a mesenteric tumor with liver metastases, a laparotomy was performed.
  • The mesenteric mass was completely resected, but additional operative procedures were not done to the liver.
  • After the operation, the patient was determined to have Stage IVB diffuse large B-cell lymphoma, and chemotherapy based on the CHOP-like regimen was given.
  • After the 8th course of such chemotherapy, he was confirmed to have achieved a complete remission by abdominal computed tomography and Gallium scintigram.The Stage IV mesenteric diffuse large B-cell lymphoma involving the liver seems to be an indication for combination therapy of surgical resection and multiagent chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Liver Neoplasms / pathology. Lymphoma, B-Cell / surgery. Lymphoma, Large B-Cell, Diffuse / surgery. Mesentery. Peritoneal Neoplasms / surgery
  • [MeSH-minor] Aged. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Humans. Male. Prednisolone / administration & dosage. Remission Induction. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17496458.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  •  go-up   go-down


30. Nakamura H, Katayose Y, Rikiyama T, Onogawa T, Yamamoto K, Yoshida H, Hayashi H, Ohtsuka H, Hayashi Y, Egawa S, Unno M: Advanced bile duct carcinoma in a 15-year-old patient with pancreaticobiliary maljunction and congenital biliary cystic disease. J Hepatobiliary Pancreat Surg; 2008;15(5):554-9
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advanced bile duct carcinoma in a 15-year-old patient with pancreaticobiliary maljunction and congenital biliary cystic disease.
  • We report a case of advanced bile duct carcinoma arising in a 15-year-old female with pancreaticobiliary maljunction and congenital biliary cystic disease.
  • Pancreaticoduodenectomy and partial resection of the liver was performed.
  • Surgical and histopathological findings indicated advanced tubular adenocarcinoma, classified as final stage IVb according to the General rules for surgical and pathological studies on cancer of the biliary tract proposed by the Japanese Society of Biliary Surgery, 5th edition, and stage IV according to the American Joint Committee on Cancer (AJCC)/International Union Against Cancer (UICC), 6th edition.
  • She underwent chemotherapy with gemcitabine HCl after discharge.
  • Although it is well known that biliary malignancies arise frequently in patients with pancreaticobiliary maljunction, it is uncommon for advanced bile duct carcinoma to occur in a 15-year-old female.
  • [MeSH-major] Adenocarcinoma / etiology. Bile Duct Neoplasms / etiology. Digestive System Diseases / complications. Liver Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Digestive Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18836813.001).
  • [ISSN] 0944-1166
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


31. Yanagawa T, Shimizu J, Dono K, Yasumoto T, Hata T, Fujino S, Kitahara T, Munakata K, Watanabe N, Takamoto K, Nagai K, Miyake M, Hata T, Kawanishi K, Ikeda K, Fujita J, Akagi K, Iwasawa T, Kitada M, Shimano T: [A case report--transarterial embolization for advanced gallbladder carcinoma with hepatic metastasis]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2711-3
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case report--transarterial embolization for advanced gallbladder carcinoma with hepatic metastasis].
  • CT revealed a primary gallbladder carcinoma Stage IVb with multiple hepatic metastases.
  • For her poor performance status, it seems to be too difficult to undergo a general chemotherapy.
  • She underwent 2 times TAE.
  • TAE may be useful for advanced gallbladder carcinoma with tumor vascularity.
  • [MeSH-major] Embolization, Therapeutic. Gallbladder Neoplasms / pathology. Gallbladder Neoplasms / therapy. Liver Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224688.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


32. Muggia FM, Blessing JA, Waggoner S, Berek JS, Monk BJ, Sorosky J, Pearl ML: Evaluation of vinorelbine in persistent or recurrent nonsquamous carcinoma of the cervix: a Gynecologic Oncology Group Study. Gynecol Oncol; 2005 Jan;96(1):108-11
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of vinorelbine in persistent or recurrent nonsquamous carcinoma of the cervix: a Gynecologic Oncology Group Study.
  • OBJECTIVE: The Gynecologic Oncology Group (GOG) has studied a number of drugs to determine their activity in patients with previously treated squamous and nonsquamous cancer arising in the uterine cervix.
  • A Phase II study with intravenous vinorelbine was initiated for this purpose in patients with Stage IVB, recurrent, or persistent nonsquamous carcinomas who had received one prior chemotherapy or were not eligible for other studies.
  • METHODS: Eligible patients had to have measurable disease, GOG performance status of 0-2 and adequate bone marrow, liver, and renal function.
  • The treatment consisted of vinorelbine 30 mg/m(2) on days 1 and 8, repeated every 21 days.
  • Tumor measurements and toxicities were recorded every treatment cycle.
  • Severe events, such as fatigue, hypertension, or pulmonary changes attributed to drug administration, occurred only in one or two instances.
  • CONCLUSION: With the dose schedule and assessment criteria employed, vinorelbine had only minimal activity in nonsquamous cancer of the cervix.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Carcinoma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Uterine Cervical Neoplasms / drug therapy. Vinblastine / analogs & derivatives. Vinblastine / therapeutic use
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adult. Aged. Carcinoma, Adenosquamous / drug therapy. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15589588.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / CA 37517
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 5V9KLZ54CY / Vinblastine; Q6C979R91Y / vinorelbine
  •  go-up   go-down


33. Park KW, Park JW, Choi JI, Kim TH, Kim SH, Park HS, Lee WJ, Park SJ, Hong EK, Kim CM: Survival analysis of 904 patients with hepatocellular carcinoma in a hepatitis B virus-endemic area. J Gastroenterol Hepatol; 2008 Mar;23(3):467-73
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival analysis of 904 patients with hepatocellular carcinoma in a hepatitis B virus-endemic area.
  • BACKGROUND AND AIM: To investigate the clinical characteristics and survival outcomes of a large cohort of hepatocellular carcinoma (HCC) patients treated at a single institute in a hepatitis B virus (HBV)-endemic area.
  • The 4-year survival rates for Child-Pugh class A patients treated by resection or transarterial chemoembolization (TACE) were 77.3% and 63.2% for those with modified International Union Against Cancer (UICC) stage I or II disease (P = 0.043), and 58.6% and 19.2% for those with modified UICC stage III disease (P < 0.001).
  • In patients with Child-Pugh class A and stage IVa, the median survival times differed between TACE and chemotherapy treatments (6.9 vs 4.0 months, P = 0.003), whereas in patients with stage IVb there was no difference between treatments (8.5 vs 6.1 months, P = 0.173) Serum alpha-fetoprotein level, presence of portal vein tumor thrombosis, Child-Pugh class, tumor, node, and metastasis stage, and the number and type of HCC were all related to prognosis.
  • CONCLUSIONS: The results of this study will be helpful in determining the survival outcomes and treatment strategies for HCC patients in HBV-endemic areas.
  • [MeSH-major] Carcinoma, Hepatocellular / mortality. Endemic Diseases. Hepatitis B / epidemiology. Liver Neoplasms / mortality
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Catheter Ablation. Chemoembolization, Therapeutic. Female. Follow-Up Studies. Hepatectomy. Humans. Kaplan-Meier Estimate. Korea / epidemiology. Male. Middle Aged. Neoplasm Staging. Patient Selection. Proportional Hazards Models. Retrospective Studies. Risk Assessment. Risk Factors. Severity of Illness Index. Time Factors. Treatment Outcome. Venous Thrombosis / etiology. alpha-Fetoproteins / metabolism

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis B.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17764529.001).
  • [ISSN] 1440-1746
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / AFP protein, human; 0 / Antineoplastic Agents; 0 / alpha-Fetoproteins
  •  go-up   go-down


34. Shim JH, Park JW, Choi JI, Park BJ, Kim CM: Practical efficacy of sorafenib monotherapy for advanced hepatocellular carcinoma patients in a Hepatitis B virus-endemic area. J Cancer Res Clin Oncol; 2009 Apr;135(4):617-25
Hazardous Substances Data Bank. NICOTINAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Practical efficacy of sorafenib monotherapy for advanced hepatocellular carcinoma patients in a Hepatitis B virus-endemic area.
  • BACKGROUND: This study was conducted to assess the efficacy and safety of sorafenib monotherapy in clinical practice settings for Korean patients with hepatocellular carcinoma (HCC) related primarily to HBV infection.
  • METHODS: Medical records of 57 consecutive patients with unresectable or metastatic HCC treated with 400 mg bid sorafenib at the National Cancer Center, Korea between June 2007 and March 2008, were retrospectively reviewed.
  • Eleven patients (19.3%) had modified UICC stage III tumors, 11 (19.3%) had stage IVa, and 35 (61.4%) had stage IVb.
  • The median times to progression (TTP) was 9.1 weeks (95% CI 3.4-14.8 weeks).
  • [MeSH-major] Benzenesulfonates / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Hepatitis B / epidemiology. Liver Neoplasms / drug therapy. Pyridines / therapeutic use. Receptors, Vascular Endothelial Growth Factor / therapeutic use
  • [MeSH-minor] Adult. Aged. Disease Progression. Female. Hepatitis C / epidemiology. Humans. Korea. Male. Middle Aged. Neoplasm Staging. Niacinamide / analogs & derivatives. Phenylurea Compounds. Retrospective Studies. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis B.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Chemother Pharmacol. 2009 Feb;63(3):459-67 [18437384.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] Oncogene. 2001 May 3;20(20):2606-10 [11420671.001]
  • [Cites] J Cancer Res Clin Oncol. 2007 Dec;133(12):937-43 [17516087.001]
  • [Cites] Cancer Sci. 2008 Jan;99(1):159-65 [17953709.001]
  • [Cites] Jpn J Clin Oncol. 2007 Oct;37(10):755-62 [17951335.001]
  • [Cites] Hepatology. 2002 Mar;35(3):519-24 [11870363.001]
  • [Cites] Lancet Oncol. 2008 Feb;9(2):117-23 [18221915.001]
  • [Cites] N Engl J Med. 2008 Jul 24;359(4):378-90 [18650514.001]
  • [Cites] J Hepatol. 2001 Sep;35(3):421-30 [11592607.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jul 15;47(5):1331-5 [10889387.001]
  • [Cites] Korean J Hepatol. 2004 Jun;10(2):88-98 [15218342.001]
  • [Cites] J Clin Oncol. 2004 Nov 15;22(22):4442-5 [15483011.001]
  • [Cites] J Gastroenterol Hepatol. 2008 Mar;23(3):467-73 [17764529.001]
  • [Cites] Bioorg Med Chem Lett. 2007 Apr 1;17(7):1843-9 [17289388.001]
  • [Cites] Cancer. 2008 Jan 15;112(2):250-9 [18041064.001]
  • [Cites] Lancet Oncol. 2001 Sep;2(9):533-43 [11905707.001]
  • [Cites] Hepatology. 1998 Sep;28(3):751-5 [9731568.001]
  • [Cites] Hepatology. 2002 May;35(5):1164-71 [11981766.001]
  • [Cites] J Clin Oncol. 2006 Sep 10;24(26):4293-300 [16908937.001]
  • [Cites] Hepatology. 2005 Nov;42(5):1208-36 [16250051.001]
  • [Cites] Hepatol Res. 2002 Dec;24(4):395-403 [12479938.001]
  • (PMID = 18846384.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor
  •  go-up   go-down


35. Snady H: Interventional endoscopy, neoadjuvant therapy and the gastroenterologist. Hematol Oncol Clin North Am; 2002 Feb;16(1):53-79
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interventional endoscopy, neoadjuvant therapy and the gastroenterologist.
  • With current treatment, survival of greater than 1 year should be anticipated for many patients with pancreatic cancer.
  • Obstructive jaundice is managed successfully with endoscopic placement of a plastic stent early in the evaluation of a patient with suspected regional pancreatic cancer, and a metal wall stent is reserved for patients with known 1997 AJCC stage IVB carcinoma or nonoperative patients.
  • Relief of biliary obstruction allows improvement in liver function and more time to evaluate tumor stage accurately to determine initial treatment (see Fig. 1).
  • A cost-effective algorithm to determine accurate stage and treatment can start with the size of the mass on initial imaging studies.
  • EUS-guided FNA represents a significant improvement over CT scan-guided FNA to make a tissue diagnosis.
  • Small pancreatic masses that would be resected regardless of whether an FNA is positive or negative require only an EUS evaluation to establish an early resectable stage.
  • Tumors reliably staged as unresectable by nonoperative imaging methods including EUS are treated with chemotherapy with or without concurrent radiotherapy because median survival of these patients is 2 years in some series.
  • For chronic pain or gastric outlet obstruction not responding or treatable by chemoradiotherapy, endoscopically guided celiac plexus nerve block and stenting improve the quality of life for patients with pancreatic cancer.
  • A team approach is required to achieve the objectives of improved quality of life, prolonged survival, and possible cure for pancreatic cancer.
  • Interpretations of disease stage based on each of these methods may overlap but are not identical and are operator dependent.
  • [MeSH-major] Adenocarcinoma / therapy. Endoscopy. Endoscopy, Gastrointestinal. Endosonography. Neoadjuvant Therapy. Pancreatic Neoplasms / therapy
  • [MeSH-minor] Ampulla of Vater / surgery. Antineoplastic Agents / therapeutic use. Autonomic Nerve Block / methods. Carcinoma, Neuroendocrine / diagnosis. Carcinoma, Neuroendocrine / therapy. Chemotherapy, Adjuvant. Cholangiopancreatography, Endoscopic Retrograde. Cholestasis / etiology. Cholestasis / therapy. Combined Modality Therapy. Common Bile Duct Neoplasms / surgery. Diagnostic Imaging / methods. Gastric Outlet Obstruction / surgery. Humans. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / therapy. Neoplasm Staging / methods. Pain Management. Palliative Care. Pancreatic Cyst / therapy. Prognosis. Radiotherapy, Adjuvant. Stents

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12063829.001).
  • [ISSN] 0889-8588
  • [Journal-full-title] Hematology/oncology clinics of North America
  • [ISO-abbreviation] Hematol. Oncol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 115
  •  go-up   go-down






Advertisement